- Home
- QNCX vs IMMX Comparison
QNCX vs IMMX Comparison
Compare QNCX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- IMMX
- Stock Information
- Founded
- QNCX 2012
- IMMX 2014
- Country
- QNCX United States
- IMMX United States
- Employees
- QNCX N/A
- IMMX N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- QNCX Health Care
- IMMX Health Care
- Exchange
- QNCX Nasdaq
- IMMX Nasdaq
- Market Cap
- QNCX 44.0M
- IMMX 50.1M
- IPO Year
- QNCX 2019
- IMMX 2021
- Fundamental
- Price
- QNCX $1.02
- IMMX $1.63
- Analyst Decision
- QNCX Strong Buy
- IMMX Strong Buy
- Analyst Count
- QNCX 5
- IMMX 1
- Target Price
- QNCX $8.00
- IMMX $7.00
- AVG Volume (30 Days)
- QNCX 138.1K
- IMMX 50.8K
- Earning Date
- QNCX 05-12-2025
- IMMX 05-08-2025
- Dividend Yield
- QNCX N/A
- IMMX N/A
- EPS Growth
- QNCX N/A
- IMMX N/A
- EPS
- QNCX N/A
- IMMX N/A
- Revenue
- QNCX N/A
- IMMX N/A
- Revenue This Year
- QNCX N/A
- IMMX N/A
- Revenue Next Year
- QNCX N/A
- IMMX N/A
- P/E Ratio
- QNCX N/A
- IMMX N/A
- Revenue Growth
- QNCX N/A
- IMMX N/A
- 52 Week Low
- QNCX $0.51
- IMMX $1.26
- 52 Week High
- QNCX $2.45
- IMMX $2.84
- Technical
- Relative Strength Index (RSI)
- QNCX 26.91
- IMMX 49.04
- Support Level
- QNCX $0.93
- IMMX $1.36
- Resistance Level
- QNCX $1.26
- IMMX $1.57
- Average True Range (ATR)
- QNCX 0.10
- IMMX 0.18
- MACD
- QNCX -0.03
- IMMX -0.00
- Stochastic Oscillator
- QNCX 18.03
- IMMX 53.70
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.